Comunicati Stampa
Salute e Benessere
Salute e Benessere
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Press ReleaseNicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations Additional pre-planned analysis of the NCX 470 Denali trial completedNCX 470 maintains robust intraocular pressure lowering at 6, 9 and 12 monthsOther analyses broadly in line with the trends seen for Mont BlancData presentations planned for upcoming ophthalmology conferencesOctober 2, 2025 – release at 7:30 am CETSophia...
Per maggiori informazioni
Sito Web
nicox.com
Ufficio Stampa
Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
Allegati
Non disponibili